Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. (NKTX) is a clinical-stage biopharmaceutical company pioneering engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. This page provides investors and industry observers with a comprehensive repository of official announcements, clinical trial updates, and strategic developments.
Access real-time updates on NK cell therapy advancements, financial results, regulatory milestones, and partnership agreements. Our curated feed ensures you stay informed about Nkarta’s proprietary cell expansion platform, pipeline progress, and innovations in off-the-shelf immunotherapy solutions.
Key content includes updates on clinical trial phases, manufacturing collaborations, scientific presentations, and corporate governance. Bookmark this page to monitor Nkarta’s progress in developing safer, more accessible cell therapies while maintaining compliance with financial disclosure standards.
Nkarta, Inc. announced its first-quarter 2021 financial results, reporting a net loss of $19.4 million, or $0.59 per share. The company has cash and equivalents of $299.7 million, projected to support operations through at least mid-2023. Key developments include FDA clearance for NKX019, a CAR NK cell therapy targeting CD19, with patient dosing expected to begin in the second half of 2021. Additionally, amendments to the NKX101 trial will streamline patient enrollment and treatment. Nkarta is collaborating with CRISPR Therapeutics to advance its cell therapy pipeline.
Nkarta, Inc. (Nasdaq: NKTX) announced that the FDA has cleared its Investigational New Drug application for NKX019, a new CAR NK cell therapy targeting CD19 in patients with relapsed or refractory B cell malignancies. This marks the company’s second IND clearance within ten months. NKX019 is designed to enhance NK cell proliferation and activity using a membrane-bound form of IL-15. The Phase 1 clinical trial for NKX019 is set to begin in the second half of 2021, reinforcing Nkarta’s commitment to developing innovative cancer therapies derived from healthy donors.
Nkarta, Inc. (Nasdaq: NKTX) reported its financial results for Q4 and FY 2020, highlighting a cash position of $315.3 million as of December 31, 2020. The company is advancing its CAR NK cell therapies, with interim clinical data for NKX101 expected by year-end 2021 and an IND application for NKX019 planned for Q1 2021. R&D expenses totaled $36.2 million for 2020, while the net loss reached $91.4 million, or $5.44 per share. Nkarta anticipates sufficient cash to sustain operations into at least mid-2023.
Nkarta, Inc. (Nasdaq: NKTX) has announced its participation in several upcoming investor conferences, highlighting its focus on advancing NK cell therapies for cancer treatment. The events include the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, featuring a fireside chat at 1:40 p.m. ET, and the Cowen 41st Annual Health Care Conference on March 3-4, 2021, with no presentation scheduled. Additionally, Nkarta will present at the Barclays Global Healthcare Conference on March 11, 2021, at 10:20 a.m. ET. Live webcasts of these presentations will be available on their website.
Nkarta, Inc. has announced the dosing of the first patient in its Phase 1 clinical trial of NKX101, targeting acute myeloid leukemia and myelodysplastic syndromes. The company ended Q3 2020 with $330.2 million in cash, sufficient to fund operations through at least mid-2023. Nkarta plans to file an IND application for NKX019 in Q1 2021, focusing on B-cell malignancies. The Q3 financials revealed a net loss of $13.7 million, or $0.44 per share, alongside R&D expenses of $9.8 million and G&A expenses of $3.9 million.
Nkarta (Nasdaq: NKTX) has initiated its first-in-human Phase 1 clinical trial of NKX101 for treating relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS). This multi-center trial aims to evaluate safety and preliminary anti-tumor activity. NKX101 is engineered to enhance natural killer (NK) cell response by targeting NKG2D, improving cytotoxic activity significantly in preclinical models. The trial addresses a critical need for effective treatments in AML patients, who have limited options and poor outcomes.
Nkarta, Inc. (Nasdaq: NKTX) has provided a preclinical update on NKX019, an investigational allogeneic cancer immunotherapy focused on treating B cell malignancies. The findings, presented at the SITC 35th Annual Meeting, indicate that NKX019 showed strong anti-tumor activity against CD19-expressing cancer models, outperforming non-engineered NK cells and demonstrating advantages over CAR T cells. Notably, NKX019 displayed reduced cytokine release syndrome risk, suggesting a favorable safety profile. Nkarta plans to file an IND application for NKX019 in Q1 2021 and initiate a Phase 1 trial for advanced B cell malignancies.
Nkarta, a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer, has announced its participation in several upcoming investor conferences.
The events include:
- Cowen 2020 IO Next Summit on November 13, 2020, at 11:45 a.m. ET
- Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 2:00 p.m. ET
- Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 9:40 a.m. ET
Audio webcasts will be available on Nkarta's website, with replays archived for about four weeks.
Nadir Mahmood, Ph.D. has been appointed as Chief Financial and Business Officer of Nkarta, Inc. (NASDAQ: NKTX), succeeding Matthew Plunkett, who stepped down to pursue other opportunities. Mahmood has been with Nkarta since 2018, contributing significantly to the company's strategy and operations. Alicia J. Hager, J.D., Ph.D. will join as Chief Legal Officer. Both leaders are expected to enhance Nkarta’s growth in developing engineered NK cell therapies for cancer.
Nkarta, Inc. (Nasdaq: NKTX) will participate in the Cantor Virtual Global Healthcare Conference on September 15, 2020, with a fireside chat presentation scheduled for 2:00 p.m. ET. The event will feature a live audio webcast available on Nkarta's website, with a replay archived for approximately four weeks.
Nkarta is focused on developing engineered natural killer (NK) cell therapies for cancer, utilizing a proprietary platform for efficient manufacturing and cell engineering aimed at enhancing tumor targeting and persistence.
FAQ
What is the current stock price of Nkarta (NKTX)?
What is the market cap of Nkarta (NKTX)?
